Clinical Trial Update: Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 study evaluating rografatinib (BAY1163877) versus chemotherapy in FGFR-positive urothelial carcinoma; the trial is completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transitional Cell Carcinoma of the Bladder
• Urothelial Carcinoma

Drugs mentioned

• rogaflatinib (BAY1163877) (rogaratinib)

Snippet

Sponsor: Bayer | Conditions: Carcinoma, Transitional Cell | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2021-12-29